Skip to main content

Advertisement

SpringerLink
Log in

HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

The selection of a systemic breast cancer therapy is based on the expression pattern of immunohistochemical prognostic markers. In our study we sought to determine whether neoadjuvant chemotherapy may alter these expression patterns within the tumors. Our hypothesis was that the expression of the immunohistochemical prognostic markers does not differ between tissue specimens before and after neoadjuvant chemotherapy. We determined the protein expression levels of estrogen receptor, progesterone receptor, Ki67, p53 and HER2/neu in the core biopsy and the resected tumor sample from 25 patients receiving neoadjuvant chemotherapy. As a control group, we analyzed sample pairs from 30 patients who did not receive neoadjuvant chemotherapy. Additionally, we determined the relative HER2/neu gene copy number by FISH and/or real-time PCR. There were no significant differences in the changes in expression patterns from the core biopsy to the treated resected tumor between those who had received neoadjuvant chemotherapy and the control group. We suggest that it is sufficient to analyze the prognostic factors from either the core biopsy prior to chemotherapy or the treated tumor sample instead of investigating both samples. This would markedly reduce the costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Albino AP, Jaehne J, Altorki N, Blundell M, Urmacher C, Lauwers G, Niedzwiecki D, Kelsen DP (1995) Amplification of HER-2/neu gene in gastric adenocarcinomas: correlation with primary site. Eur J Surg Oncol 21:56–60

    Google Scholar 

  2. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831

    Google Scholar 

  3. Baselga J (2001) Phase I and II clinical trials of trastuzumab. Ann Oncol 12 [Suppl 1]:S49–S55

    Google Scholar 

  4. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17:3058–3063

    Google Scholar 

  5. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA (1991) Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 63:601–608

    Google Scholar 

  6. Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis OPA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE (1999) Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 6:25–28

    Google Scholar 

  7. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 19:403–410

    Google Scholar 

  8. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493

    Google Scholar 

  9. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V (1997) Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 44:185–192

    Google Scholar 

  10. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singetary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469

    Google Scholar 

  11. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, De Mascarel I, Coindre JM (1996) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, Mib-1, pS2 and GST pi. Br J Cancer 74:1458–1465

    Google Scholar 

  12. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC, Dowsett M (1999) Quantitative changes in cytological markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53:51–59

    Google Scholar 

  13. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier J-M, Bonvalot S, Gignoux M (1994) Pathologic assessment of tumor regression after preoperative chemotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73:2680–2686

    Google Scholar 

  14. Nahta R, Esteva FJ (2003) HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9:5078–5084

    Google Scholar 

  15. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659–2671

    Google Scholar 

  16. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241–2251

    Google Scholar 

  17. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, Ferriere JP, De Latour M, Chollet P (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22:1319–1325

    Google Scholar 

  18. Pohl G, Rudas M, Taucher S, Stranzl T, Steger GG, Jakesz R, Pirker R, Filipits M (2003) Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78:97–103

    Google Scholar 

  19. Reles A, Marx D, Meden H (1991) C-erbB2 oncogene expression in ovarian cancers. Arch Gynaecol Obstet 250:183–184

    Google Scholar 

  20. Remmele W, Stegner HE (1987) Vorschlag zur einheitlichen Definierung eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8:138–140

    Google Scholar 

  21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235:177–182

    Google Scholar 

  22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Google Scholar 

  23. Surbone A, Norton L (1993) Kinetic concepts in the treatment of breast cancer. Ann N Y Acad Sci 698:48–62

    Google Scholar 

  24. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlböck M, Jakesz R (2003) Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10:91–98

    Google Scholar 

  25. Taucher S, Rudas M, Mader RM, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner T, Fitzal F, Kandioler D, Wenzel C, Steger GG, Mittlböck M, Jakesz R (2003) Influence of neoadjuvant chemotherapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat 82:207–213

    Google Scholar 

  26. Tyson FL, Boyer CM, Kaufman R, O’Briant K, Cram G, Crews JR, Soper JT, Daly L, Fowler WC Jr, Haskill JS (1991) Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol 165:640–646

    Google Scholar 

  27. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X (2002) HER2 in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94:2169–2173

    Google Scholar 

  28. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Google Scholar 

  29. Winston JS, Ramanaryanan J, Levine E (2004) HER-2/neu evaluation in breast cancer: are we there yet? Am J Clin Pathol 121 [Suppl 1]:S33–S49

    Google Scholar 

Download references

Acknowledgements

The authors are grateful to Dr. Christel Weiß, Department for Medical Statistics, University Hospital Mannheim, for statistical advice.

Author information

Authors and Affiliations

  1. Pathologisches Institut, Universitätsklinikum Mannheim gGmbH, Theodor-Kutzer-Ufer 1–3, 68167, Mannheim, Germany

    Norbert Arens, Uwe Bleyl & Ralf Hildenbrand

Authors
  1. Norbert Arens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uwe Bleyl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ralf Hildenbrand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norbert Arens.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arens, N., Bleyl, U. & Hildenbrand, R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 446, 489–496 (2005). https://doi.org/10.1007/s00428-005-1244-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-005-1244-0

Keywords

Search

Navigation